Treatment of epilepsy using a targeted p38γ kinase gene therapy

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)
73 Downloads (Pure)

Abstract

Hyperphosphorylated microtubule-associated protein tau has been implicated in dementia, epilepsy, and other neurological disorders. In contrast, site-specific phosphorylation of tau at threonine 205 (T205) by the kinase p38γ was shown to disengage tau from toxic pathways, serving a neuroprotective function in Alzheimer's disease. Using a viral-mediated gene delivery approach in different mouse models of epilepsy, we show that p38γ activity-enhancing treatment reduces seizure susceptibility, restores neuronal firing patterns, reduces behavioral deficits, and ameliorates epilepsy-induced deaths. Furthermore, we show that p38γ-mediated phosphorylation of tau at T205 is essential for this protection in epilepsy, as a lack of this critical interaction reinstates pathological features and accelerates epilepsy in vivo. Hence, our work provides a scope to harness p38γ as a future therapy applicable to acute neurological conditions.

Original languageEnglish
Article numbereadd2577
Pages (from-to)1-8
Number of pages8
JournalScience Advances
Volume8
Issue number48
DOIs
Publication statusPublished - 2 Dec 2022

Bibliographical note

Copyright the Author(s) 2022. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

Fingerprint

Dive into the research topics of 'Treatment of epilepsy using a targeted p38γ kinase gene therapy'. Together they form a unique fingerprint.

Cite this